These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22589265)

  • 21. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
    Sarzi-Puttini P; Filippucci E; Adami S; Meroni PL; Batticciotto A; Idolazzi L; De Lucia O; Talavera P; Kumke T; Grassi W
    Adv Ther; 2018 Aug; 35(8):1153-1168. PubMed ID: 30043210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study.
    Szekanecz Z; Koncz Á; Dunkel J; Vencovský J;
    Clin Exp Rheumatol; 2019; 37(6):1010-1018. PubMed ID: 30963993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
    Furst DE; Shaikh SA; Greenwald M; Bennett B; Davies O; Luijtens K; Staelens F; Koetse W; Bertin P
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):151-60. PubMed ID: 25302624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
    Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
    Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
    Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
    Curtis JR; Chen L; Luijtens K; Navarro-Millan I; Goel N; Gervitz L; Weinblatt M
    Arthritis Rheum; 2011 Aug; 63(8):2203-8. PubMed ID: 21484766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
    Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
    Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.
    Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H
    Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
    Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
    Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Kynaston-Pearson FJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD007649. PubMed ID: 25231904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial.
    Pfeil A; Nussbaum A; Renz DM; Hoffmann T; Malich A; Franz M; Oelzner P; Wolf G; Böttcher J
    Arthritis Res Ther; 2020 Oct; 22(1):229. PubMed ID: 33023661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Iwata S; Hanami K; Fukuyo S; Miyagawa I; Yamaguchi A; Kawabe A; Saito K; Tanaka Y
    Arthritis Res Ther; 2021 Jun; 23(1):154. PubMed ID: 34074349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Certolizumab pegol: in rheumatoid arthritis.
    Duggan ST; Keam SJ
    BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.
    Combe B; Furst DE; Keystone EC; van der Heijde D; Luijtens K; Ionescu L; Goel N; Emery P
    Arthritis Care Res (Hoboken); 2016 Mar; 68(3):299-307. PubMed ID: 26238672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Certolizumab pegol in rheumatoid arthritis: current update.
    Fechtenbaum M; Md Yusof MY; Emery P
    Expert Opin Biol Ther; 2014 Jun; 14(6):841-50. PubMed ID: 24654999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.
    Kumar N; Naz S; Quinn M; Ryan J; Kumke T; Sheeran T
    Adv Ther; 2018 Sep; 35(9):1426-1437. PubMed ID: 30076523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.